Crescent Biopharma reports news about its clinical-stage oncology pipeline, including CR-001, a PD-1 x VEGF bispecific antibody, and antibody-drug conjugate programs such as CR-002 and CR-003. Company updates commonly cover clinical trial activity in solid tumors, pipeline combinations, collaboration activity, financial results, and business highlights.
Recurring corporate announcements also include investor conference presentations and equity inducement awards under the company’s employment inducement incentive plan. These updates reflect Crescent’s status as a Nasdaq-listed biotechnology issuer focused on cancer therapeutics.
GlycoMimetics, Inc. (Nasdaq: GLYC) reports promising results from a Phase 1b trial of GMI-1359 at Duke University Cancer Center. Initial findings reveal on-target effects, immune activation, and cell mobilization in two patients treated with the drug, a dual antagonist of E-selectin and CXCR4. No significant toxicities were noted, and the drug demonstrated an acceptable safety profile. Dorothy Sipkins, MD, will present these results at the AACR Annual Meeting, highlighting the potential of GMI-1359 to improve responses in metastatic breast cancer therapies.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that an abstract for its preclinical study on GMI-1757 has been accepted for presentation at the AACR 2021 Annual Meeting. GMI-1757, a glycomimetic with dual antagonism to E-selectin and galectin-3, showed promising results in a pancreatic adenocarcinoma model, with 50% partial regressions and a ~99% reduction in median tumor volume. The compound improved anti-PD-L1 therapeutic activity, leading to favorable immune conditions. The presentation will be available online starting April 10, 2021.
GlycoMimetics (Nasdaq: GLYC) announced its abstract presentations at the AACR 2021 Annual Meeting, featuring an interim analysis of the Phase 1b study on GMI-1359, a dual antagonist targeting E-selectin and CXCR4 for treating cancers involving the bone. Also highlighted is GMI-1757, a novel compound with effects on fibrosis and therapeutic activity in pancreatic cancer. CEO Rachel King emphasized the significance of these studies in advancing treatment options for cancers with bone involvement. Both presentations are set for April 10, 2021.
GlycoMimetics (Nasdaq: GLYC) announced the dosing of the first patient in a Phase 1 clinical trial of APL-106 (uproleselan injection) for relapsed or refractory acute myeloid leukemia (AML) in China. This trial, part of a bridging study combining uproleselan with chemotherapy, aims to evaluate the drug's pharmacokinetics and safety. Uproleselan has received Breakthrough Therapy designation from both the U.S. FDA and the CDE in China. The trial is led by Professor Jianxiang Wang at the Chinese Academy of Medical Sciences, highlighting significant progress in addressing unmet medical needs for AML patients.
GlycoMimetics, Inc. (Nasdaq: GLYC) reported its financial results for Q4 and the full year ended December 31, 2020. The company had cash and cash equivalents of $137.0 million as of year-end. Revenue for 2020 was $10.2 million, significantly higher than 2019, reflecting progress in collaborations for uproleselan and GMI-1687. The pivotal trial for uproleselan continues to enroll patients, with completion expected in H2 2021. The company shifted focus from rivipansel to GMI-1687, which may better suit outpatient care for sickle cell patients.
GlycoMimetics, Inc. (Nasdaq: GLYC) announces participation in three virtual healthcare conferences in March 2021. Key events include:
- Cowen 41st Annual Health Care Conference: March 1-4, featuring Eric Feldman on a Leukemias Panel on March 3.
- H.C. Wainwright Global Life Sciences Conference: March 9-10, with CEO Rachel King presenting a corporate overview.
- 33rd Annual Virtual Roth Conference: March 15-17, where Rachel King will again present.
GlycoMimetics focuses on novel glycomimetic drugs for hematology-oncology.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call on March 2, 2021, at 8:30 a.m. ET to report its fourth quarter and year-end 2020 financial results. The call can be accessed domestically at (844) 413-7154 or internationally at (216) 562-0466 with participant code 1034166. A webcast replay will be available for 30 days post-call. The company focuses on developing novel glycomimetic drugs for unmet medical needs in hematology-oncology, including the evaluation of uproleselan in clinical trials.
GlycoMimetics, Inc. (Nasdaq: GLYC) has promoted Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer, effective immediately. Dr. Feldman, previously Vice President, Global Clinical Development, is noted for his expertise in developing therapies for leukemias. He will lead the uproleselan program, currently in Phase 3 trials. Dr. Helen Thackray, former Chief Medical Officer, will leave the company after 15 years. Uproleselan, an investigational treatment for AML, has received Breakthrough Therapy designation from the FDA, showing promising results in clinical trials.
GlycoMimetics (Nasdaq: GLYC) presented new data on rivipansel at the 62nd ASH Annual Meeting, confirming its efficacy in treating acute vaso-occlusive crises (VOC) in sickle cell disease. The analysis from an Open Label Extension trial revealed that early treatment with rivipansel resulted in a median hospital stay of 80.89 hours, compared to 103.97 hours for placebo, a significant difference. The pediatric data showed a reduction of 29.3 hours in the median time to resolution of pain. CEO Rachel King emphasized ongoing FDA interactions for future clinical development.
GlycoMimetics (Nasdaq: GLYC) announced promising results for its investigational drug uproleselan at the 62nd ASH Annual Meeting. The drug significantly reduced tumor burden and improved survival rates in animal models of acute myeloid leukemia (AML) when combined with venetoclax and a hypomethylating agent. CEO Rachel King emphasized the potential for further clinical trials to explore this combination. Uproleselan is currently in Phase 3 development for AML and has received Breakthrough Therapy designation from the FDA.